Precision BioSciences Inc (DTIL)
9.60
-0.12
(-1.23%)
USD |
NASDAQ |
Apr 26, 11:18
Precision BioSciences Debt to Equity Ratio: 1.188 for Dec. 31, 2023
Debt to Equity Ratio Chart
Historical Debt to Equity Ratio Data
| Date | Value |
|---|---|
| December 31, 2023 | 1.188 |
| September 30, 2023 | 0.7695 |
| June 30, 2023 | 0.6556 |
| March 31, 2023 | 0.5543 |
| December 31, 2022 | 0.3677 |
| September 30, 2022 | 0.2628 |
| June 30, 2022 | 0.2147 |
| March 31, 2022 | 0.0356 |
| December 31, 2021 | 0.0272 |
| September 30, 2021 | 0.0242 |
| June 30, 2021 | 0.0242 |
| Date | Value |
|---|---|
| March 31, 2021 | 0.00 |
| December 31, 2020 | 0.00 |
| September 30, 2020 | 0.00 |
| June 30, 2020 | 0.00 |
| March 31, 2020 | 0.00 |
| December 31, 2019 | 0.00 |
| September 30, 2019 | 0.00 |
| June 30, 2019 | 0.00 |
| March 31, 2019 | 4.842 |
| December 31, 2018 | 0.00 |
Debt to Equity Ratio Definition
The debt to equity ratio measures the (Long Term Debt + Current Portion of Long Term Debt) / Total Shareholders' Equity. This metric is useful when analyzing the health of a company's balance sheet.
Debt to Equity Ratio Range, Past 5 Years
--
Minimum
Jun 2019
1.188
Maximum
Dec 2023
0.2171
Average
0.0242
Median
Jun 2021
Debt to Equity Ratio Benchmarks
| Altimmune Inc | 0.00 |
| BioVie Inc | -- |
| Adial Pharmaceuticals Inc | -- |
| Gritstone Bio Inc | 0.7742 |
| Humacyte Inc | -- |
Debt to Equity Ratio Related Metrics
| Total Assets (Quarterly) | 159.78M |
| Total Liabilities (Quarterly) | 140.92M |
| Shareholders Equity (Quarterly) | 18.86M |
| Current Ratio | 2.728 |
| Net Debt Paydown Yield | -0.10% |